Monday, November 8, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1180
Better Websites, Better Match: Assessing Quality of Rheumatology Fellowship Websites
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1338
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1240
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)- 8:30AM-10:30AM
-
Abstract Number: 1322
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1173
Bringing Reproductive Health Guidelines into Fellowship Training: A National Survey of Adult and Pediatric Rheumatology Fellows and Program Directors to Assess Educational Need and Inform Curriculum Development
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1093
Cardiovascular and Lipid Biomarker Distributions in Inflammatory Arthritis
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1319
Cardiovascular Risk Reclassification According to Six Traditional Cardiovascular Risk Algorithms and a Carotid Ultrasound in Psoriatic Arthritis Patients
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1032
Causes of Death Among Populations with Systemic Lupus Erythematosus by Race and Ethnicity
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)- 8:30AM-10:30AM
-
Abstract Number: 1005
CD209/CD14+ Dendritic Cells Characterization in Rheumatoid and Psoriatic Arthritis Patients: Activation, Synovial Infiltration and Therapeutic Targeting
Innate Immunity Poster (0992–1006)- 8:30AM-10:30AM
-
Abstract Number: 1368
Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)- 8:30AM-10:30AM
-
Abstract Number: 1099
Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1245
Characteristics of RA Patients Treated with JAK Inhibitors Before versus After VTE Warnings: Results of a Real-World Multicentric Study
RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)- 8:30AM-10:30AM
-
Abstract Number: 1407
Characterization of Synovial Fluid T Cells in Polymyalgia Rheumatica: Implication of Th1 and Tc1 Effector Memory Profiles
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)- 8:30AM-10:30AM
-
Abstract Number: 1056
Characterization of the Patterns of Care, Access and Direct Costs of Systemic Lupus Erythematosus in Brazil: Findings from the Macunaíma Study